000 | 02000 a2200529 4500 | ||
---|---|---|---|
005 | 20250514051414.0 | ||
264 | 0 | _c20030102 | |
008 | 200301s 0 0 eng d | ||
022 | _a1369-7137 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPan, H-A | |
245 | 0 | 0 |
_aFlow resistance in carotid and middle cerebral arteries in postmenopausal women: a comparative study of tibolone and continuous combined hormone replacement therapy. _h[electronic resource] |
260 |
_bClimacteric : the journal of the International Menopause Society _cSep 2002 |
||
300 |
_a259-65 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial | ||
650 | 0 | 4 | _aBlood Flow Velocity |
650 | 0 | 4 |
_aBrain _xblood supply |
650 | 0 | 4 |
_aCarotid Artery, Common _xdrug effects |
650 | 0 | 4 |
_aCarotid Artery, Internal _xdrug effects |
650 | 0 | 4 |
_aCholesterol _xblood |
650 | 0 | 4 |
_aCholesterol, HDL _xblood |
650 | 0 | 4 |
_aCholesterol, LDL _xblood |
650 | 0 | 4 |
_aCoronary Circulation _xdrug effects |
650 | 0 | 4 | _aDrug Administration Schedule |
650 | 0 | 4 |
_aEstrogen Receptor Modulators _xpharmacology |
650 | 0 | 4 | _aEstrogen Replacement Therapy |
650 | 0 | 4 |
_aEstrogens, Conjugated (USP) _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aMedroxyprogesterone Acetate _xadministration & dosage |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMiddle Cerebral Artery _xdrug effects |
650 | 0 | 4 |
_aNorpregnenes _xpharmacology |
650 | 0 | 4 | _aPostmenopause |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 |
_aPulsatile Flow _xdrug effects |
650 | 0 | 4 | _aSingle-Blind Method |
650 | 0 | 4 | _aTreatment Outcome |
650 | 0 | 4 |
_aTriglycerides _xblood |
650 | 0 | 4 |
_aVascular Resistance _xdrug effects |
700 | 1 | _aWang, S-T | |
700 | 1 | _aChen, C-H | |
700 | 1 | _aPai, M-C | |
700 | 1 | _aWu, M-H | |
700 | 1 | _aHuang, K-E | |
773 | 0 |
_tClimacteric : the journal of the International Menopause Society _gvol. 5 _gno. 3 _gp. 259-65 |
|
999 |
_c12226750 _d12226750 |